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Abstract
The effects of two different mitochondrial-targeted drugs, SS-31 and NMN, were
tested on Old mouse hearts. After treatment with the drugs, individually or Combined,
heart function was examined by echocardiography. SS-31 partially reversed an age-related decline in diastolic function while NMN fully reversed an age-related deficiency
in systolic function at a higher workload. Metabolomic analysis revealed that both
NMN and the Combined treatment increased nicotinamide and 1-methylnicotinamide
levels, indicating greater NAD+ turnover, but only the Combined treatment resulted
in significantly greater steady-state NAD(H) levels. A novel magnetic resonance spectroscopy approach was used to assess how metabolite levels responded to changing cardiac workload. PCr/ATP decreased in response to increased workload in Old
Control, but not Young, hearts, indicating an age-related decline in energetic capacity.
Both drugs were able to normalize the PCr/ATP dynamics. SS-31 and NMN treatment
also increased mitochondrial NAD(P)H production under the higher workload, while
only NMN increased NAD+ in response to increased work. These measures did not
shift in hearts given the Combined treatment, which may be owed to the enhanced
NAD(H) levels in the resting state after this treatment. Overall, these results indicate
that both drugs are effective at restoring different aspects of mitochondrial and heart
health and that combining them results in a synergistic effect that rejuvenates Old
hearts and best recapitulates the Young state.
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strong evidence for this hypothesis and shown that NMN supplementation bolsters NAD+ availability and improves many classical

Cardiovascular disease remains the major cause of mortality in older

signs of aging in mice (Mills et al., 2016). NMN supplementation has

adults (Heron & Anderson, 2016; Tinetti et al., 2012), eclipsing all

also been shown to partially restore heart function in a mouse model

forms of cancer by the age of 75 (Roger et al., 2011). Furthermore,

of heart failure (Lee et al., 2016).

age-related decline in heart function, which includes dysfunction in

Although NMN and SS-31 both target mitochondria, they do so

both diastole and systole (Dai, Chen, Johnson, Szeto, & Rabinovitch,

via different mechanisms of action. Thus, we hypothesized that the

2012), has been shown to be strongly associated with frailty

drugs would differ in effect on the heart and may have a synergistic

(Leibowitz et al., 2016). Because of the immense burden of heart

effect when applied together. We sought to compare and contrast

dysfunction on the elderly population, the development of treat-

the mechanism and effects of these drugs in order to better under-

ments that can improve heart health in aged individuals remain a top

stand each individually and how age-related deficits in heart func-

priority for extending human healthspan.

tion can be addressed.

The majority of the heart's volume consists of cardiomyocytes

Because mice recapitulate many aspects of human aging

(Zhou & Pu, 2016), which must meet the incredible energetic de-

(Vanhooren & Libert, 2013), including a general decline in heart

mand of continuous contraction and relaxation throughout an en-

function (Dai et al., 2012), they are an excellent model for deter-

tire lifespan. To meet this energetic need, heart tissue has one of

mining whether these drugs have the potential to rejuvenate aged

the highest mitochondrial densities found in the body (Benard et al.,

hearts in humans and to determine the mechanisms of this im-

2006). As cells age, nicotinamide dinucleotide (NAD+) levels, ATP

provement. To test the effects of these drugs on the aged heart,

output, and mitochondrial biogenesis decrease, while oxidative

mice aged 24 months at the start of treatment (Old) were randomly

stress, mtDNA damage, and mitochondrial structural alterations

sorted into Control, SS-31, NMN, or Combined (SS-31 + NMN) treat-

increase (Chistiakov, Sobenin, Revin, Orekhov, & Bobryshev, 2014).

ment groups for comparison with mice 5–6 months of age (Young).

Based on these physiological features, it has long been hypothe-

Treatment doses of SS-31 and NMN were in alignment with those

sized that mitochondrial fitness is key to maintaining heart health

that have previously been shown to be effective in other healthspan

(Herrmann & Decherd, 1939). According to this hypothesis, treat-

measures (Chiao et al., 2020; Mills et al., 2016). In vivo magnetic res-

ments that can restore mitochondrial parameters to more youthful

onance spectroscopy is typically used to examine ATP and PCr levels

states in aged cardiomyocytes have the potential to repair the func-

in muscle tissue, though when applied to beating hearts the spectra

tion of aged hearts.

must be voxel-localized and timed to coincide with heart and pulmo-

In this study, we set out to determine the functional and meta-

nary cycles. In this report, we further developed and applied for the

bolic effects on aged mouse hearts of two mitochondrial-targeted

first time an MRS technique to determine how additional heart me-

drugs proposed to treat age-related dysfunction: SS-31 and nicotin-

tabolites, including nicotinamide nucleotides, respond to an increase

amide mononucleotide (NMN).

in cardiac workload, defined by an accelerated heart rate, in vivo.

SS-31, also known as elamipretide, is a synthetic tetrapeptide

This analysis was coupled with measurements by echocardiography

consisting of D-arginine, 2′,6′-dimethyl-l-tyrosine, lysine, and phe-

and liquid chromatography tandem mass spectrometry (LC-MS/MS)

nylalanine that associates with the head group of cardiolipin, an es-

to obtain an integrated view of changes resulting from age and drug

sential phospholipid specific to the mitochondrial inner membrane

treatment from the metabolic to the functional level in the heart.

(Szeto, 2014). Previous testing of SS-31 in mammals has shown that
the drug decreases oxidative stress (Hou et al., 2016) and protects
against ischemia–reperfusion injury (Cai et al., 2018), although the
specific mechanisms by which the drug elicits these changes are
still being actively investigated. There are indications that a combination of preventing cytochrome c peroxidase activity, promoting

2

|

R E S U LT S

2.1 | SS-31 and NMN treatments result in different
functional improvements

cristae, and electron transport chain complex organization, as well
as influencing other mitochondrial proteins, contributes to these

Echocardiography was performed on all mice at baseline and again

beneficial effects (Birk, Chao, Bracken, Warren, & Szeto, 2014;

on Old mice after 8 weeks of treatment. Diastolic function was as-

Szeto, 2014). We have recently demonstrated that SS-31 improves

sessed by determining the ratio of blood flow across the mitral valve

diastolic function and reduces oxidative stress in the hearts of aged

in early diastole (Ea) to the flow in late diastole (Aa). Ea/Aa is one of

mice when delivered for 8 weeks (Chiao et al., 2020).

the primary markers used when assessing diastolic function in human

NMN is a naturally occurring nucleotide precursor of NAD+ that

patients (Mitter, Shah, & Thomas, 2017) and is the parameter of di-

is generated via the NAD+ salvage pathway (Yoshino, Baur, & Imai,

astolic function that has been used in composing a comprehensive

2018). NMN and its precursor nicotinamide riboside (NR) have been

frailty index of mouse aging (Kane, Keller, Heinze-Milne, Grandy, &

hypothesized to improve mitochondrial health by increasing cellular

Howlett, 2019). Old Control mice had a significantly (p < 0.05) lower

NAD+ availability and therefore improving energetic capacity and

Ea/Aa compared to Young mice at their baseline, indicating a de-

activating sirtuin deacetylase activity. Recent studies have provided

cline in diastolic function with age. As found previously (Chiao et al.,
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2020), Old mice treated with SS-31 showed a significant (p < 0.05)

agent dobutamine at a concentration that produced higher heart

improvement in Ea/Aa, restoring it approximately halfway to that of

rates within the normal physiological range (Figure 1b). Long-term

Young Ea/Aa values, whereas the Control and NMN-treated groups

assessment of heart rates showed that dobutamine administra-

showed no change in this parameter (Figure 1a). The Combined

tion results in a similar significant (p < 0.001) increase in heart rate

treatment group recapitulated the Ea/Aa change resulting from

across all groups (Figure S1). There were no significant differences

SS-31 alone but did not show any further improvement.

in fractional shortening between the groups at the low work state

Systolic function was assessed by measuring percent fractional

or within groups at treatment endpoints relative to their baselines

shortening (i.e., the degree to which the ventricular lumen closes

(Figure S2). Under higher workload conditions, however, Old Control

during systole) from echocardiograms. Since anesthetized mice have

mice manifested a significantly (p < 0.0001) lower percent fractional

subphysiological heart rates, alterations in systolic function may not

shortening than Young mice, indicating a decline in high work sys-

be manifested under these low work conditions. Thus, fractional

tolic function with age. SS-31 treatment did not significantly affect

shortening was also measured following injection of the ionotropic

fractional shortening, but NMN and the Combined treatments both

F I G U R E 1 Effect of SS-31 and NMN on heart function. (a) Ea/Aa ratio at baseline (treatment day 0) and endpoint (8 weeks of treatment)
and (b) percent fractional shortening at low work (-dobutamine) and high work (+dobutamine) at the 8 week treatment endpoint, measured
by echocardiography. N = 29 Young, 49 Old Control, 29 Old SS-31, 28 Old NMN, 10 Old Combined. (c) High work (+dobutamine) percent
fractional shortening measured by echocardiography in Young and Old mice at 0, 1, 6, 10, 20, 30, 42, and 56 days of NMN treatment.
N = 8 Young, 19 Old. (d) Ratio of heart weight (g) to tibia length (mm) assessed at endpoint (8 weeks of treatment) as a measure of cardiac
hypertrophy. N = 21 Young, 21 Old Control, 16 Old SS-31, 15 Old NMN, 14 Old Combined.
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significantly (p < 0.005) improved high work percent fractional

By the first method, the total NAD(H) pool of the heart ap-

shortening in Old mice, fully restoring it to Young levels (Figure 1b).

peared to decline with age (Figure 2a), as has been reported else-

While our previous studies have shown that SS-31 induces a

where (Braidy et al., 2011). Neither SS-31 nor NMN treatment alone

partial effect on diastolic function after 4 weeks of treatment and

resulted in any change to total NAD(H). However, when NMN and

appears to reach its peak effect at 8 weeks (Chiao et al., 2020), it was

SS-31 were given in combination, there was a significant (p < 0.05)

unknown on what timescale the cardiac functional improvements in-

increase in NAD(H) levels. The ratio of NAD+ to NADH did not

duced by NMN occur. To test this, Young and Old mice were treated

change significantly in any of the groups. NADP+ also did not show

with NMN and tested at regular intervals to determine changes

any significant changes between the groups (Figure 2b), and NADPH

in their high work percent fractional shortening (Figure 1c). After

was undetectable by this assay. Of the assayed NAD precursors,

10 days of treatment, Old mice treated with NMN showed a sig-

only nicotinamide (NAM) showed a difference between groups, with

nificant (p < 0.05) improvement in high work fractional shortening,

a significant (p < 0.02) decrease in levels between Young and Old

restoring it to Young levels. This remained constant, with no further

Control hearts, and a restoration by both NMN and Combined treat-

enhancement from prolonged treatment. Young fractional shorten-

ments (p < 0.05) (Figure 2c). NMN, nicotinamide riboside (NR), and

ing was unaffected by NMN treatment. Young mice were also given

nicotinic acid (NA) also showed the same trend of a decrease with

SS-31 to determine whether there was any effect on diastolic func-

age and restoration by NMN and Combined treatments but did not

tion, but the Ea/Aa ratio was not significantly changed after 4 or

individually reach significance (Figure 2d–f). Nicotinamide adenine

8 weeks of SS-31 treatment (Figure S3). The persistence of the func-

dinucleotide (NAAD) did not follow this trend and did not show any

tional improvement induced by NMN treatment was also examined.

significant changes (Figure 2g).

In contrast to SS-31, which we have previously shown to maintain

In the general targeted metabolomics assay, which primarily

half its functional effect 4 weeks after cessation of treatment (Chiao

assessed metabolites involved in protein and carbohydrate energy

et al., 2020), NMN's effect on aged hearts is more transient. After

metabolism, 26 metabolites showed significant (FDR < 0.1) changes

stopping NMN treatment, high work fractional shortening remained

when comparing Young to Old Control mice (Table 1). None of the

the same one day later but then declined at approximately the rate it

treatments appeared to have a significant effect on shifting the

had improved after starting treatment, matching the baseline for Old

overall metabolome of Old hearts back toward the Young state, and

hearts after 10 days without treatment (Figure S4).

each showed only a few significant (FDR < 0.1) changes. Most nota-

Relative to Young mice, Old Control mice showed a significant

bly, the NMN and Combined treatments resulted in a sharp increase

(p < 0.05) increase in cardiac hypertrophy, measured as the ratio of

in 1-methylnicotinamide (MNA) (FDR < 0.0001) in Old mice com-

heart weight to tibia length (Figure 1d). NMN and the Combined

pared to Young, Old Control, and Old SS-31 mice (Figure 3a). SS-31

treatments appeared to reduce this hypertrophy and partially re-

treatment resulted in modest increases in xanthine and choline

store heart weight/tibia length to the Young state, but SS-31 alone

(FDR < 0.1) levels (Figure 3b,c). Intriguingly, the Combined treatment

did not have a significant effect.

did not recapitulate the SS-31-induced changes and instead showed

Mitochondrial function in isolated cardiomyocytes from Old

similar levels of both choline and xanthine to the Old Control and

Control and NMN-treated hearts was assessed by Seahorse assay

Old NMN groups. The full set of comparisons between all groups

(Agilent Technologies, Santa Clara, CA). While we have previously

can be found in the Appendix S1. We investigated whether the

shown by this method that SS-31 normalized age-related increases

change in MNA levels could be due to a difference in nicotinamide

in basal respiration and proton leak (Chiao et al., 2020), NMN treat-

N-methyltransferase (NNMT) levels; however, this enzyme was not

ment did not appear to have any such effect, as mitochondrial oxy-

detectable in any mouse hearts by Western blot (Figure S6) or shot-

gen consumption appeared unchanged from the Control group by all

gun proteomics (data not shown).

measures (Figure S5).

Analysis of general trends in canonical pathways from this
dataset was performed based on all changes p < 0.05 (unadjusted

2.2 | Metabolomic analyses of hearts reveal unique
changes resulting from SS-31 and NMN treatments

p-values) in Young relative to Old Control hearts using Ingenuity
Pathway Analysis (Qiagen, Hilden, Germany). This revealed that the
major metabolic pathways being affected by age included glycolysis,
citrulline biosynthesis, phosphatidylcholine biosynthesis, and oth-

Analysis of cardiac metabolic differences at the endpoint of treat-

ers (Figure 3d). Quantification of relative changes in the canonical

ment was completed by two LC-MS/MS methods: (a) a focused anal-

pathways heatmap was split into metabolites that increased with age

ysis of NAD-related metabolites and (b) a general screening of 369

(Figure 3e) and those that decreased with age (Figure 3f). While there

common metabolites.

were suggestive trends toward reversal of the age-related changes

F I G U R E 2 Analysis of endpoint NAD+-related metabolite levels. Endpoint (8 weeks of treatment) levels of (a) NAD(H), (b) NADP+, (c)
NAM, (d) NMN, (e) NR, (f) NA, and (g) NAAD in mouse hearts as measured by targeted LC-MS/MS. The height of the stacked columns in (a)
indicates the total NAD+NADH content. The significance noted is based on these total values. N = 11 Young, 10 Old Control, 11 Old SS-31,
11 Old NMN, 8 Old Combined.
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TA B L E 1 Significant age-related
metabolomics changes in mouse hearts

Fold change relative to old control
Metabolite

Young

Old SS−31

Old NMN

Old
combined

5-Aminovaleric acid

2.09(0.38)

1.79(0.38)

1.76(0.38)

1.81(0.41)

Carnosine

2.00(0.15)

0.78(0.16)

0.84(0.16)

0.94(0.17)

N-Formylmethionine

1.93(0.32)

1.60(0.32)

1.62(0.33)

1.79(0.35)

Hypotaurine

1.92(0.21)

1.16(0.22)

1.23(0.22)

1.35(0.23)

Beta-alanine

1.78(0.15)

0.95(0.15)

1.21(0.15)

1.12(0.16)

Anserine

1.64(0.10)

0.80(0.11)

0.89(0.11)

0.82(0.11)

Adenine

1.56(0.16)

1.09(0.17)

1.03(0.17)

1.21(0.18)

Cholesterol sulfate

1.46(0.19)

1.14(0.19)

1.08(0.19)

1.11(0.20)

Ethylmalonic acid

1.39(0.18)

1.00(0.18)

1.29(0.18)

1.06(0.19)

5′-Methylthioadenosine

1.35(0.14)

1.00(0.14)

0.96(0.14)

1.05(0.15)

ADP

1.32(0.08)

1.07(0.08)

1.02(0.08)

1.02(0.09)

Citrulline

1.29(0.10)

1.01(0.10)

1.04(0.10)

1.13(0.11)

L-Glutamic acid

1.20(0.10)

1.11(0.10)

0.98(0.10)

0.94(0.11)

Choline

1.14(0.06)

1.19(0.06)

0.99(0.06)

1.02(0.07)

L-Serine

0.81(0.10)

1.06(0.10)

0.90(0.10)

0.89(0.11)

Sedoheptulose 7-phosphate

0.77(0.13)

1.20(0.13)

0.93(0.13)

1.04(0.14)

3-Methylhistidine

0.65(0.16)

0.89(0.16)

0.97(0.16)

0.87(0.18)

Pipecolic acid

0.63(0.20)

0.97(0.20)

0.86(0.20)

0.90(0.21)

Dihydroxyacetone
phosphate

0.59(0.14)

0.72(0.14)

0.93(0.14)

0.81(0.16)

Lactose/trehalose

0.55(0.25)

0.81(0.26)

0.99(0.26)

1.14(0.28)

Glyceraldehyde-3-phosphate

0.54(0.16)

0.71(0.16)

0.91(0.16)

0.78(0.17)

Erythrose 4-phosphate

0.50(0.28)

0.75(0.29)

0.91(0.29)

1.03(0.31)

Glucose-6-phosphate

0.49(0.29)

0.77(0.29)

0.93(0.29)

1.05(0.31)

Trimethyloxamine

0.47(0.31)

1.33(0.31)

1.14(0.31)

1.07(0.34)

Glucose-1,6-bisphosphate

0.40(0.32)

0.56(0.32)

0.90(0.32)

0.61(0.34)

L-Cystine

0.32(0.43)

0.85(0.43)

0.58(0.44)

0.62(0.47)

Values are untransformed fold changes with standard errors in parentheses. Bold numbers indicate
significance (FDR < 0.1). Ordered by fold change. Full results can be found in the Appendix S1.

to these pathways, treatment effects did not reach significance in

phosphocreatine (PCr) to γ-ATP (given as PCr/ATP; Figure 4b). This

the quantification. Mean difference plots for each comparison are

measurement provides an assessment of how effectively the heart

provided in the supplemental data (Figure S7).

can respond to increased work by determining the degree to which
the high-energy phosphates stored in PCr are depleted from car-

2.3 | Magnetic resonance spectroscopy probes
dynamic metabolic shifts in vivo

diomyocytes under increased demand for ATP. While Young mouse
hearts showed no change in PCr/ATP in response to increased workload, Old Control mouse hearts had a significant (p < 0.05) decrease
in PCr/ATP following dobutamine injection, indicating a diminished

31

P-magnetic resonance spectroscopy (MRS) was applied at the

ability of the heart to handle such a workload with age. Although

treatment endpoint in order to probe how metabolites in the heart

still showing a slight decrease in PCr/ATP at the higher workload,

respond to a dobutamine-induced increase in cardiac workload in

the SS-31, NMN, and Combined treatments all appeared to mitigate

vivo. Image-Selected In Vivo Spectroscopy (ISIS) was used to collect

the age-related change, and PCr/ATP in the treated groups was not

data localized to the heart with minimal inclusion of surrounding tis-

significantly different from the Young state or their predobutamine

sues. A representative heart-localized voxel and resulting MRS spec-

baselines.

trum from this technique are shown in Figure 4a.

In order to analyze how less abundant metabolites in the heart

The principle difference in the energetic response to the in-

respond to increased cardiac workload in these mice, peaks cor-

creased heart rate was measured as the ratio of the peak areas of

responding to chemical standards of α-ATP, UDP-glucose, NAD+,

WHITSON et al.
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F I G U R E 3 General metabolomics analysis of mouse hearts. Endpoint (8 weeks of treatment) levels of (a) 1-methylnicotinamide (MNA),
(b) xanthine, and (c) choline as measured by general targeted metabolomics. N = 12 Young, 10 Old Control, 12 Old SS-31, 11 Old NMN, 8 Old
Combined. Means are calculated from postprocessed values and are not log2-transformed. (d) Heatmap of metabolic changes in the top 20
canonical pathways based on all changes with an unadjusted p < 0.05 when comparing Young to Old Control. (e and f) Quantification of the
heatmap, separated into metabolites that decreased (e) or increased (f) with age.
NADH, NADP+, and NADPH were fit to the experimental spec-

measured by MRS. This is unsurprising given the known issues with

tra for quantification using a custom model in OriginPro software

extracting and preserving these metabolites from tissue samples

(OriginLab, Northampton, MA). An additional peak corresponding

(Lu, Wang, Chen, Hui, & Rabinowitz, 2018) and thus may actually

to mitochondrial NAD(P)H was also fit to the data, based upon our

demonstrate a strength of the in vivo MRS method. Mitochondrial

prior study demonstrating the presence of this peak in vivo, which

NAD(P)H cannot be distinguished from the cytosol-localized mole-

has an altered chemical shift relative to cytosolic NAD(P)H due to

cules by the metabolomics method and thus was not included in the

the unique environment of the mitochondrial matrix (Conley, Ali,

comparison. Overall, this comparison supports the relative quantifi-

Flores, Jubrias, & Shankland, 2016). A representative fit of exper-

cation of these metabolites from in vivo heart MRS spectra.

imental data using this model is shown in Figure 4c. To assess the

The MRS data showed a trend of NAD+ remaining stable or de-

performance of this technique for analyzing these metabolites, MRS

creasing slightly in Young hearts with higher workload but increasing

results from Old Control mice prior to dobutamine injection were

in Old Control hearts (p = 0.066) (Figure 4e). SS-31 and the Combined

compared with those from the general metabolomics screen, which

treatment appeared to reverse this age-related change in NAD+ dy-

also analyzed NAD(P)(H) and UDP-glucose (Figure 4d). Relative lev-

namics. Conversely, NMN treatment did not reverse the age-related

els (normalized to mean NAD+ for comparison across methods) of

change and the increase in NAD+ at higher workload in these mice

NAD+, NADH, and UDP-glucose determined by both techniques

was significantly (p < 0.05) different from the Young state at higher

were remarkably similar, but there was a large discrepancy in

workload. Mitochondrial NAD(P)H also showed changing dynam-

NADP+ and NADPH levels, which were much higher relatively when

ics with drug treatment (Figure 4f). While Young and Old Control

8 of 14
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F I G U R E 4 Magnetic resonance measurements of dynamic mitochondrial metabolism. (a) Representative 1H-magnetic resonance imaging
of mouse chest cavity, heart voxel localization for ISIS, and resulting 31P spectrum. (b) Change in PCr/ATP ratio after injection of dobutamine.
N = 11 Young, 11 Old Control, 11 Old SS-31, 13 Old NMN, 10 Old Combined. (c) Representative image of the automated fitting model. (d)
Comparison of MRS and metabolomics Old Control results. N = 11 MRS, 10 metabolomics. (e and f) Change in (e) NAD+ and (f) mitochondrial
NAD(P)H after injection of dobutamine. N = 11 Young, 10 Old Control, 9 Old SS-31, 11 Old NMN, 10 Old Combined.
hearts had a trend of slightly decreased mitochondrial NAD(P)H

the data imply that the drugs use two independent mechanisms to

with the increased heart rate, SS-31 and NMN-treated hearts ap-

achieve these functional benefits. Furthermore, since the drugs only

peared to reverse this trend (p = 0.074 and p < 0.05, respectively),

showed an effect in Old hearts, this appears to be a true rejuvena-

as these treatments increased mitochondrial NAD(P)H in response

tion of heart function in both cases.

to a higher workload. Interestingly, the Combined treatment did not

In this cohort of mice, we found that NMN and the Combined

recapitulate the individual results of SS-31 and NMN and instead

treatment were effective at reducing age-related hypertrophy of the

showed mitochondrial NAD(P)H levels that were unchanged when

heart while SS-31 alone was not. However, in other cohorts of mice

dobutamine was applied. Other metabolites did not show a signifi-

we have previously observed a modest but significant reduction in

cant difference between groups with increased workload, and these

hypertrophy following SS-31 treatment (Chiao et al., 2020). Given

results are presented in Figure S8.

the small difference in magnitude between these new results and
those already published, we believe this difference is primarily based

3

|

DISCUSSION

3.1 | SS-31 and NMN improve different aspects of
heart health

upon statistical variation and not the underlying biology.
NMN appears to have a much more acute effect on the heart
than SS-31. While NMN achieves its peak functional effect after
just 10 days of treatment, we have previously observed that SS-31
treatment takes approximately 8 weeks to reach its peak effect on
the heart (Chiao et al., 2020). NMN's effect was halved by 6 days

SS-31 and NMN treatments distinctly improve diastolic and higher

after treatment cessation and completely gone after 10 days,

workload systolic function, respectively. Since giving the drugs in

whereas a partial SS-31 effect persisted for several weeks after ces-

combination conferred both diastolic and systolic improvements, but

sation of treatment (Chiao et al., 2020). These differing timelines fit

neither prevented nor further added to the individual improvements,

with the hypothesis that SS-31 carries out its effects by repairing

|
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mitochondria efficiency and reducing oxidative stress, followed by

to be a restoration of an age-related loss in the metabolite and could

myocardial remodeling (Chiao et al., 2020), whereas NMN primarily

be due to changes in phospholipid production induced by SS-31's

works by boosting NAD(H) biosynthesis and thus enhancing myo-

remodeling of the mitochondrial inner membrane. Conversely, the

cardial energetic supply via oxidative phosphorylation.

increase in xanthine is a further movement away from the Young

Consistent with these proposed mechanisms, we did not detect

state and the reason for this change is unclear. Adenine is one source

any difference in mitochondrial coupling/efficiency in the Seahorse

of xanthine, by its deamination to hypoxanthine (Harrison, 2002),

assay with unstimulated cardiomyocytes isolated from NMN-treated

and more adenine is expected to be used for NAD+ synthesis with

hearts. This is in clear contrast to SS-31, which improved proton

the addition of NMN, providing one potential explanation for the

leak and respiratory control ratio in the same assay (Zhang et al.,

NMN treatment preventing the SS-31-induced increase in xanthine.

2020). We believe this is consistent with mitochondrial remodeling

Overall, the differences in xanthine and choline appear to be minor

by SS-31 that does not occur following NMN treatment. However,

metabolic consequences of the drugs but seemingly unrelated to the

this does not mean that NMN does not have any effect on the mito-

functional improvements in the heart.

chondria, as discussed below.

Although a wide selection of metabolites was screened, there are
more that could be assessed to provide valuable information on the

3.2 | Metabolic crosstalk between SS-31 and
NMN and the fate of NAD+

aging heart and the effect of these drugs. Lipid metabolism is an area
we believe demands further investigation in future studies with this
model system. Measurement of metabolic enzyme levels and activity
could also provide valuable information on the mechanisms of age-re-

The observation that NAM and MNA concentrations increased after

lated dysfunction and the restorative properties of these drugs.

NMN treatment is unsurprising, given that both are steps along the
breakdown pathway of NAD+ (Bender, 2003). Thus, the increase
in both metabolites is an expected result of increased NAD+ bio+

synthesis and greater turnover of NAD from its use as an enzyme

3.3 | SS-31 and NMN restore PCr/ATP dynamics
in the heart

cofactor, primarily for sirtuin deacetylases and poly ADP-ribose
polymerases (PARPs) (Pillai, Isbatan, Imai, & Gupta, 2005). This en-

In this study, we applied in vivo MRS to demonstrate that there is

hanced turnover of NAD+ may explain why NMN treatment does

an age-related shift in the dynamics of PCr/ATP in response to in-

not significantly increase resting NAD(H) levels, as noted here and

creased cardiac workload. Old Control hearts showed a drop in PCr/

in previous study (Mills et al., 2016). However, it is less clear why

ATP with a higher workload, whereas this parameter remained sta-

NMN and SS-31 given in combination did significantly increase the

ble in Young hearts. From this, we can conclude that mitochondria

NAD(H) pool when neither drug alone did. This would appear to in-

in Old hearts are less able to meet the energetic demand of a high

dicate a synergistic effect of the drugs. One plausible explanation is

work state and PCr decreases as a consequence of its high-energy

that SS-31's demonstrated reduction of oxidative stress (Chiao et al.,

phosphates being utilized to maintain ATP status in myofibrils faster

2020; Hou et al., 2016) results in less PARP activation and therefore

than oxidative phosphorylation can restore it. The attenuation of the

less NAD+ breakdown, allowing it to accumulate to higher levels in

effect of age on the PCr/ATP dynamics by SS-31 and NMN treat-

the cell.

ment, both individually and in combination, suggests that both drugs

Since NNMT, the enzyme that converts NAM to MNA and removes it from reentering the NAD+ salvage pathway of synthesis

improve the ability of cardiac mitochondria to meet the metabolic
demand of the increased workload.

(Bockwoldt et al., 2019), was at undetectable levels in the heart, if
present at all, conversion to MNA is likely occurring elsewhere in the
mice, with the MNA found in the heart having entered from the circulation. One concern with increased MNA synthesis is the potential

3.4 | Proposed model of dynamic mitochondrial
metabolism changes

for depletion of methyl donors in the cell (Pissios, 2017). Neither the
NMN or Combined treatment group showed a significant decrease

While limited by signal to noise and high variance, the novel MRS

in S-adenosyl methionine (Appendix S1), the major methyl donor of

method that we describe here presents an exciting new means to

the cell and the one utilized for MNA synthesis, so it does not appear

analyze metabolic changes in response to a stimulus in live mice. We

that methyl donors were depleted to a significant level. However,

believe that the mitochondrial NAD(P)H peak we have described

enhanced usage of S-adenosyl methionine likely does explain why

consists primarily of NADH based on its dynamic behavior here and

the slight increase in choline induced by SS-31 treatment was pre-

in our prior study in which it was first described (Conley et al., 2016),

vented by simultaneous treatment with NMN, since choline is used

although we are unable to definitively say to what degree NADPH

to produce S-adenosyl methionine (Zeisel & Corbin, 2012).

contributes to the peak. Taking all of the above results into consid-

Why SS-31 treatment causes an increase in xanthine and choline,

eration, we propose the following model to contextualize the differ-

and why the addition of NMN prevents the accumulation of xan-

ences in metabolic shifts seen between the mouse groups with the

thine, is less clear. In the case of choline, the SS-31 effect appears

increase in cardiac workload.

10 of 14
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Young hearts have a sufficient NAD(H) pool and undamaged

while also exhibiting improved diastolic function. Thus, the combi-

mitochondria, which provide them with adequate ATP production

nation of SS-31 and NMN, which together appear to increase fuel

+

capacity to meet a higher workload. As a result, NAD and PCr do

supply and coupling efficiency while limiting excess oxidative stress,

not show any significant shifts from increasing workload, while mi-

provides a synergistic improvement in energetic capacity so that

tochondrial NAD(P)H trends toward a slight decrease due to greater

supply can fully meet demand.

utilization. Old Control hearts have a diminished NAD(H) pool, so
higher workload places a greater strain on the mitochondrial ATP
production capacity, as evidenced by accumulating NAD+, decreasing PCr, and reduced high work systolic function.

3.5 | Mechanisms of diastolic improvement by SS31

SS-31 in Old hearts appeared to improve the efficiency of ATP
production in the mitochondria, as it normalized the shifts in PCr

It is less clear whether the metabolic changes described above are

and NAD+ that resulted from increasing the cardiac workload. A rea-

directly responsible for the improvement in diastolic function result-

son for this might be that mitochondrial NAD(P)H showed a reverse

ing from SS-31 treatment. Metabolic changes certainly do play a role

in the direction of change with increasing workload following SS-31

in diastolic dysfunction, as it is well established that ADP levels have

treatment, indicating that the supply-demand matching of NADH

a regulatory role in sarcomere stiffness with higher ADP inhibiting

production was improved, with supply now outpacing demand

relaxation and increasing diastolic stiffness (Sequeira et al., 2015).

rather than lagging behind. This implies a potential improvement in

The previously reported effects of age and SS-31 on mitochondrial

the efficiency of the tricarboxylic acid (TCA) cycle. Although several

coupling in cardiomyocytes (Zhang et al., 2020) are consistent with

TCA cycle intermediates were evaluated by the general metabolo-

a role for altered ADP levels in the changes in diastolic function re-

mics screen, which did not show differences resulting from SS-31

ported here. However, we did not detect any significant changes in

treatment (Appendix S1), this does not rule out the involvement

ATP or ADP at rest in Old hearts treated with SS-31 in our metabo-

of the TCA cycle since these measurements were only collected

lomics analysis (Appendix S1). Furthermore, we found by MRS that

from tissue taken at rest. We have also recently demonstrated that

PCr/ATP at rest was unaltered by age or SS-31 (Figure S10), also in-

there is a direct interaction between SS-31 and TCA cycle enzymes

dicating a lack of difference in resting ADP levels. In addition, the

involved in alpha-ketoglutarate metabolism (Chavez et al., 2019).

effects on SS-31 mitochondrial coupling we have reported appear

Other reasons why ATP production may be enhanced by SS-31

to be rapid onset, while the improvements in diastolic dysfunction

lie in its direct effects on the mitochondrial inner membrane and

require longer term treatment. An alternative mechanism, for which

inner membrane proteins. We have recently demonstrated that

we have previously published direct evidence (Chiao et al., 2020), is

SS-31 is highly effective at preventing an age-associated excess

the effect of SS-31 on post-translational modification of myofibrillar

protein leak across the mitochondrial inner membrane, which ap-

contractile proteins. In particular, SS-31 greatly reduced age-related

pears to be mediated by the adenine nucleotide translocase (Zhang

increases in the oxidation state of the proteome, including contrac-

et al., 2020). Reduced production of reactive oxygen species, which

tile proteins, and restored the phosphorylation levels of the sarco-

otherwise cause damage to mitochondrial proteins and consume

meric protein myosin-binding protein C, cardiac-type (cMyBP-C) to

NADPH through antioxidant regeneration, also occurs and is an-

the young state. These changes are consistent with improved relaxa-

other likely mechanism for the improved efficiency (Chiao et al.,

tion of the cardiac sarcomere, a critical aspect of diastolic function

2020). However, these improvements are apparently not sufficient

(Gilda & Gomes, 2017; McNamara, Singh, & Sadayappan, 2019).

for SS-31 to restore higher work systolic function.
NMN also normalized PCr levels under the higher workload in
Old hearts, but by a seemingly different mechanism than SS-31.

3.6 | Conclusions

NMN-treated hearts were the only group to show a simultaneous
increase in both NAD+ and mitochondrial NAD(P)H content. This

By testing SS-31 and NMN together in mice, we were able to pro-

could indicate that NMN-treated hearts responded to increased

vide new insight into the effects and mechanisms of each drug in the

+

workload by rapidly increasing the synthesis of NAD in order to

heart. Excitingly, this work shows that NMN and SS-31 can be given

raise mitochondrial NAD(H) levels and provide a higher capacity for

in combination to rejuvenate both diastolic and systolic aspects of

work in situ. This seemingly improved capacity allowed these hearts

ventricular function, boost NAD(H) content better than NMN given

to match the Young state in high work systolic function.

alone, and stabilize mitochondrial NAD(H) dynamics. These results

The Combined treatment in Old hearts appeared to best recapit-

may have strong clinical relevance and imply that synergistic treat-

ulate the Young state. This group did not show any significant shifts

ment with the two drugs in combination may be more effective at

in PCr, NAD+, or mitochondrial NAD(P)H following the increase in

treating age-related heart dysfunction than either given alone. This

workload, which we believe to be due to the higher energetic ca-

is also an illustration that complimentary use of appropriate drug

pacity afforded by the restoration of resting NAD(H) levels. These

combinations may become a more general model for achieving opti-

hearts matched the high work systolic function of the Young state,

mal healthspan extension.
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E X PE R I M E NTA L PRO C E D U R E S

4.1 | Animal use and care

11 of 14

the low work state. Analysis of systolic function included an injection of 3 µg/g body weight dobutamine in order to induce a higher
cardiac workload and analyze maximal function. High work echocardiography was performed once the heart rate increased at least

All mice used in this study were males of the C57BL/6 strain. Young

100 bpm and remained stable.

and Old mice were obtained from the National Institute on Aging
Charles River colony and further aged to 5–6 and 24 months, respectively, before starting the study. Mice were kept under diur-

4.4 | Euthanasia and tissue handling

nal conditions with ad libitum food and water. Mice were housed
at 20°C under diurnal conditions in an AAALAC-accredited facility

Mice were euthanized by live cervical dislocation. Hearts were im-

under Institutional Animal Care and Use Committee supervision

mediately removed, flushed with PBS to remove blood, and weighed.

with ad libitum access to food and water. Old mice were randomly

A 2-mm section was removed from the ventricles for histology, and

assigned to Control, SS-31, NMN, or Combined treatment groups.

the remaining tissue was cut into ~2 mm3 chunks and snap-frozen in
liquid N2 to store for further processing. Frozen tissue was mechani-

4.2 | Drug administration and treatment groups
SS-31 was provided by Stealth BioTherapeutics (Newton, MA) and
administered at a 3 mg/kg body weight/day dosage through osmotic

cally lysed into a fine powder using a Tissuelyser II (Qiagen) prior to
preparation for LC-MS/MS-based measurements.

4.5 | Targeted NAD+ metabolomics

minipumps (ALZET, Cupertino, CA) implanted surgically under the
skin on the left dorsal side of the mice. Pumps were modified to

Levels of NAD+, NADH, NADP+, NADPH, NA, NAAD, NAM, NR, and

replace the metal stem with PEEK tubing, according to the manu-

NMN at treatment endpoints were measured by Ultra Performance

facturer's instructions, for compatibility with magnetic resonance

Liquid Chromatography coupled with Mass Spectrometry as previ-

spectroscopy. After 4 weeks, the original minipump was surgically

ously described (Trammell & Brenner, 2013), with some modifications.

removed and a new minipump was implanted to continue the SS-31

Under CO2 vapor, lysed tissue was dissolved in chilled buffered meth-

administration for another 4 weeks.

anol solution (75% methanol, 25% 10 mM HEPES pH 7.8) spiked with

NMN was obtained from the Imai laboratory (Washington

stable isotope-labeled internal standards of NAD+ and NADH for nor-

University in St. Louis, MO) and administered through ad libitum

malization, and brought to a final concentration of 250 mg/ml. Samples

drinking water with a concentration based on each cage's measured

were then spun down repeatedly at 16,000 g for 10 min and trans-

water consumption rate and mean mouse body weight to approxi-

ferred to new tubes until no pellet formed. Pellets were saved for pro-

mate a 300 mg/kg body weight/day dose. NMN water was the only

tein quantification as an additional normalization step. Supernatants

source of hydration given to these mice and was replaced every

were filtered using 4-mm and 0.22-µM syringe filters (MilliporeSigma,

3–7 days based upon prior tests showing that it remains stable in

Burlington, MA). 5 µl of the extract was separated on a BEHAmide

water at room temperature for at least 1 week (Mills et al., 2016).

column (Waters, Milford MA) using an Acquity UPLC (Waters) and an-

Combined treatment mice received SS-31 through minipumps

alyzed with a Xevo TQ (Waters) in multiple reaction monitoring mode

while simultaneously receiving NMN water as their exclusive source

(MRM). LC solvents were A: H2O with 10 mM ammonium acetate and

of hydration as described above.

0.4% NH4OH; and B: 95:5 acetonitrile H2O with 10 mM ammonium

Initially, two different controls groups were used: mice with osmotic minipumps containing only saline as a control for SS-31 and

acetate and 0.4% NH4OH for all metabolites. Samples were run alongside an external standard curve for quantification.

mice without minipumps receiving standard water as a control for
NMN. However, an analysis of functional and MRS results revealed
that there were no significant differences between these two con-

4.6 | General targeted metabolomics

trol groups (Figure S9). Thus, the two control groups were integrated
into a single control for all treatment conditions.

Heart tissue samples were homogenized in water and methanol with
spiked stable isotopes as internal QC standards. Samples were puri-

4.3 | Echocardiography

fied by pelleting proteins, drying of the solution via Speedvac (Thermo
Fisher Scientific), and reconstituting in HILIC solvent. Protein pellets
were analyzed by BCA (Thermo Fisher Scientific) as a normalization

Mice were anesthetized by 0.75%–2% isoflurane, and echocardi-

step. LC-MS/MS-based metabolomics targeting a list of 369 metabo-

ography was performed using a Siemens Acuson CV-70 (Munich,

lites was performed on a system consisting of Shimadzu Nexera XR

Germany) equipped with a 13 MHz probe. Heat support and heart

LC-20AD pumps (Kyoto, Japan) coupled to a Sciex (Framingham, MA)

rate monitoring were provided throughout the procedure with

6500+ triple quadrupole spectrometer operating in scheduled MRM

mouse heart rates being maintained in the range of 450–550 bpm at

detection mode through the Sciex Analyst 1.6.3 software, as described

12 of 14

|

WHITSON et al.

elsewhere (Nagana Gowda, Djukovic, Bettcher, Gu, & Raftery, 2018).

for Metabolic Imaging at the University of Washington. Mice were

The system includes a dual-column setup with dedicated columns for

placed into a custom apparatus with coils for both 1H and 31P NMR

positive ionization mode and negative ionization mode. Metabolite

and anesthetized minimally via nose cone with 0.75%–1.5% isoflu-

concentrations were quantified using Sciex MultiQ uant 3.0.2 software.

rane. Heart rate, respiratory rate, and temperature were monitored

Analysis of the dataset was performed using R (version 3.6.0). In

using a Model 1030 Monitoring & Gating System (Small Animal

order to remove the systematic variation between samples, we per-

Instruments, Inc., Stony Brook, NY). Anesthesia was adjusted as

formed a Cyclic LOESS normalization, which had good performance

needed to maintain respiratory rate at 100–130 bpm. Temperature

using a MS benchmark dataset (Li et al., 2017). This normalization

was also adjusted as needed to keep mice at a body temperature

step is implemented using the limma R package (Ritchie et al., 2015).

of 37°C. Mice were equipped with an intraperitoneal catheter con-

Missing values are known to be a problematic issue for mass spec-

nected to a line of dobutamine to allow for remote injection without

trometry-based data. Previous studies have summarized the three

altering the position of the mouse.

missing value mechanisms in terms of MS-based data (Lazar, Gatto,

Triggered, multi-slice, gradient echo, 1H-magnetic resonance

Ferro, Bruley, & Burger, 2016; Wei et al., 2018): Missing Completely

images were acquired (TR = 160 ms, TE = 4 ms, with a 2 mm slice

At Random (MCAR), which corresponds to the combination and

thickness) to place a voxel isolating the heart for

31

P ISIS (Ordidge,

31

propagation of multiple minor errors or stochastic fluctuations.

Connelly, & Lohman, 1986).

Each missing value cannot be directly explained by the nature of

sult of 96 averages (acquiring a total of 768 acquisitions) using 2 ms

the feature or by its measured intensity. Missing At Random (MAR)

hyperbolic secant 180 o pulses during localization, but a nominal 90°

assumes the possibility of a variable being missing is determined

square (50 μs), non-selective pulse for readout. Typical voxel size

by other observed variables, for example, inaccurate peak detec-

P ISIS spectra (TR = 3 s) were the re-

was ~0.8 cm3 to sample the entire heart. Data were collected over

tion. Missing Not At Random (MNAR) corresponds to censored

a 38-min acquisition with gating based upon heart rate and respi-

missing values caused by compound abundances that are below

ratory rate to ensure the position of the heart was constant across

the limits of quantification (LOQ), a.k.a. left-censored data. For the

measurements. Following the first acquisition, mice were injected

metabolomics data, the missing value mechanism is believed to be

with 5 µg/g dobutamine. The second acquisition was started once

MNAR. All the metabolites with >40% missingness were excluded,

the elevated heart rate became stable.

and a total of 191 metabolites were included in the imputation step

Manual phase adjustment of the spectra, alignment of PCr to

(roughly 0.9% of the data is missing values after filtering). We used

−2.54 ppm, and quantification of PCr and γ-ATP integrals were per-

a quantile regression approach for the imputation of left-censored

formed in TopSpin (Bruker, Billerica, MA). Baseline correction of

missing data (QRILC), which has been suggested as the favored im-

spectra was performed using Mnova software (MestreLab Research,

putation method for left-censored MNAR data (Wei et al., 2018).

S.L., Santiago de Compostela, Spain).

Briefly, QRILC performs imputation by replacing missing values

OriginPro software (OriginLab Corporation) was used to

with random draws from a truncated distribution with parameters

model the fitting of α-ATP, NAD+, cytosolic NADH, NADP+, cyto-

estimated using quantile regression. This was implemented using

solic NADPH, UDP-glucose, and mitochondrial NAD(P)H peaks to

the imputeLCMD R package. Imputation was performed after the

the baseline-corrected experimental spectra for quantification of

cyclic LOESS normalization. We fit a linear model to the normalized

these molecules. Lorentzian peaks were positioned and modeled as

and imputed metabolomic data using the Bioconductor limma pack-

singlets, doublets, or quartets based upon analysis chemical stan-

age while adjusting the preparation batch and protein concentra-

dards on the instrument under physiological (12 mM Mg2+, pH 7.4)

tion as covariates in our model. The limma package uses empirical

conditions (Figure S10). Peak width was variable across different

Bayes moderated statistics, which improves power by ‘borrowing

experimental spectra but was kept consistent for NAD+, cytosolic

strength’ between metabolites in order to moderate the residual

NADH, NADP+, cytosolic NADPH, and UDP-glucose within each

variance (Smyth, 2004). Sample size for each group after removing

fit. Mitochondrial NAD(P)H peak width was allowed to vary within

outliers was Young = 12, Old Control = 10, Old NMN = 11, Old

1.5- to threefold that of the other peaks. Best fits were generated

SS-31 = 12, Old Combined = 8. False discovery rate (FDR) was lim-

automatically based on this model, with no manual adjustment used.

ited to 10% using the Benjamini–Hochberg method.
Heatmap generation was performed in R using the “heatmap”
function to create a row-scaled image based upon the top 20 sig-

Peaks were integrated automatically, and non-ATP metabolites were
normalized to α-ATP for relative quantification. OriginPro macros
are available upon request.

nificantly altered canonical pathways in the Young vs. Old Control
comparison as determined by IPA (Qiagen).

4.7 |

31

P-magnetic resonance spectroscopy

4.8 | Statistical analysis
Statistical analysis of large-scale metabolomic data is described in
the above section. Other statistical analyses were performed using

Magnetic resonance spectroscopy was performed on live mice

Prism (GraphPad Software, San Diego, CA). One-way ANOVAs were

using a 4.7 Tesla instrument operated by the Translational Center

used for measurements with a single time point or state per group,
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and two-way ANOVAs were used to compare measurements with
multiple time points or states for each group. One-sample t tests
were used to determine whether delta means were significantly different from 0. All results are plotted as means ± SEM.
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